A Placebo-Controlled Double-blind Parallel-group 18 Month Study To Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease

Brief description of study

This is a research study to evaluate the safety and effectiveness of the study drug BAN2401.BAN2401 is given by an intravenous infusion, which is an injection into a vein. The infusion will drip through the infusion tubing for about 60 minutes. During the study drug period, you will receive study drug or placebo injections, every 2 weeks for up to 18 months during the main study period.

Clinical Study Identifier: s19-00304
ClinicalTrials.gov Identifier: NCT03887455
Principal Investigator: Martin Sadowski.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.